Association of Breast Cancer with Hormonal Contraceptive Use Among Women Between the Ages of 15 To 65 Years Abia State, Nigeria

Emeonye Odochi Peace[*]

Department of Nursing Sciences, Abia State University Uturu, Abia State, Nigeria

[*]**Corresponding author:** Emeonye Odochi Peace, Department of Nursing Sciences, Abia State University Uturu, Abia State, Nigeria.

Citation: *Peace, E. O. (2025). Association of Breast Cancer with Hormonal Contraceptive Use Among Women Between the Ages of 15 To 65 Years Abia State, Nigeria. J of Clin Nur Rep, 4(1), 01-07.*

Abstract

Breast cancers are two of the leading causes of cancer deaths in women, accounting for more than 40% of all women's cancer and about two-thirds of cancer. deaths. The risk of breast cancer appears to increase with duration of use of hormonal contraceptives, however, after stopping taking it, the risk of invasive cancer declines, returning to the same as women who have never taken the pill 10 or more years after stopping.

Objectives: *Aimed to determine the prevalence of breast cancer with hormonal contraceptives use on women between 15-65years.*

Method: *The researchers adopted descriptive study, 740 participated in the research study and sampling technique was applied to make sure the target population had opportunity of participation. A well-structured questionnaire and preformed as tool for data collection.*

Result: *A total of 608(109.3) participants used contraceptives and between 10years 181 participants used the commodity. On breast examination, 83.4% heard normal breast in a visual inspection. 87.27% of participants heard a normal breast color. 77.03 heard no abnormal breast discharge while 22.97% said they were experiencing breast discharge.78.32% are not breast feeding while 21% were breast feeding mothers and are eligible for the screening. Kruskal Wallis H test as well as Mann-Whitney U test was employed. With a p-value of 0.038, there is enough evidence to infer that when one began to use hormonal contraceptives influences incidence of breast cancer.*

Conclusion: *Breast cancer has killed too many women either as a result of hormonal contraceptives or other causes.*

Keywords: Breast Cancer, Hormonal Contraceptives, Women's Health, Cancer Risk, Oral Contraceptives, Epidemiology, Contraceptive Use, Cancer Prevention, Public Health

Introduction

Cancer is a proliferation of the abnormal cells in the body, this condition affects both women and men leading to increase mortality of death in both sexes. Breast cancer is the leading cause of cancer in women worldwide, a multifactorial disease with multiple biological profiles could lead to breast cancer). Other factors act with a relative lower increase risk including endogenous and exogenous hormones especially oral contraceptive pills could be responsible in part for the burden of breast cancer.

Hormonal contraceptive contains synthetic versions of these female hormones that could potentially also increase cancer risk. They contain estrogen and progesterone which stimulate the development and growth of some cancers (e.g., cancers that express receptors for these hormones, such as breast cancer, which was reinforced by the recent classification of oral contraceptives (OC) as carcinogenetic agents .Breast cancer is a hormonally sensitive tumour, and the prognosis of women with current or recent breast cancer may worsen with use of the combined pill.

Walker, et al. (2015) states that the Low-dose methods of contraception, pills, IUDs, and implant, have been found to increase the risk of breast cancer in women [1]. Kirtlys (2014) talks about these new findings from a Denmark study. Jones, stated that the risk of breast cancer and hormonal family planning commodity, have now 50 years of data on the topic of hormonal family planning pills and the risk of breast cancer [2]. Largely, the studies have suggested that there's no significant increased risk of breast cancer in birth control pill users except maybe in women who used pills starting early in their teens, used them for a long time, and use them into their 40s. Recently, a study from Denmark looked at 1.8 million women between the ages of 15 to 49 who had used hormonal contraception between 1995 and 2012.Stating that the extra risk of breast cancer in women of this age group who took hormonal birth control of any type during this time period was 13 extra breast cancers per 100,000 women per year, that's a very small number, 13, out of a pretty big number, 100,000. That is, for every 100,000 women using hormonal birth control, there are 68 cases of breast cancer annually compared to 55 cases a year among non-users. Another way to crunch these numbers is to say there was one extra breast cancer for every 7,690 women using hormonal contraception. Summarily, for the users of hormonal patches, the extra breast cancers were 5 per 100,000, but it ranged from 1 fewer and 11 more, and essentially it wasn't different from women not using hormonal birth control, this is not clear, because the hormonal patch is kind of like the hormonal pill and for women using vaginal rings, there were two fewer breast cancers with statistical ranging from 32 fewer to 28 more and the same kind of numbers were seen for women using contraceptive implants or injections. There were about 5 to 10 fewer breast cancers, but the ranges were so large that there really wasn't an increase or a decrease. Hormonal IUD users had about the same increase as pill users with about 16 extra breast cancers per 100,000 women. Importantly, the risk for women under 35 years of age was 2 extra breast cancers per 100,000 women per year, a really small number.

According to Gierisch, Coeytaux, Urrutia, et al. (2013), Young women had a lower risk of breast cancer on hormonal contraception than older women and women who had used hormonal contraception for a long time, meaning 10 years or more, had a slightly larger absolute risk of contracting breast cancer than women who only used it a short time. So, considering a significant risk is 1 extra in 10 and low risk is 1 extra in 100[3]. A very low risk is 1 extra in 1,000, and an extremely low risk is 1 extra per 10,000. Breastfeeding decreases the risk of breast cancer, and certainly women who breastfeed are less likely to use hormonal birth control. Havrilesky, Moorman, Lowery, et al (2013) states that Over the past 20 years, researchers have been more interested in the progestin component of the hormonal contraception [4]. They thought that the risk for breast cancer was all about estrogen, but progestin also use in hormonal birth control seems to add a little risk as well. So, there's a possible biological reason for this very small increase in breast cancer in hormonal contraception users. In fact, women who have the breast cancer (BRCA) gene for breast and ovarian cancer have been suggested to take birth control pills because even if the risk of breast cancer is slightly greater, the risk of ovarian cancer, a cancer that's hard to detect and hard to treat, is so much less on birth control pills. Bernstein (2009), showed that taking the combined contraceptive pill (which contains oestrogen and progestogen) can increase your risk of breast cancer.

In a group of 10,000 women who don't use the combined pill, about 40 will probably develop breast cancer between the ages of 30 also a group of 10,000 women who do use the combined pill between the ages of 30s, about 54 will develop breast cancer between the ages of 30 and 39. So, using the combined pill during this time means about 14 extra cases of breast cancer are diagnosed in every 10,000 women. (Shah, Borenstein and Dubois 2005). Hunter, et al (2010) said that the equivalent to about 1 extra woman in every 1,000 taking the combined may develop breast cancer [5]. As the global burden of disease shifts from infectious diseases to non-communicable diseases (NCDs), cancer has increasingly become a major contributor to morbidity and mortality in low-income and middle-income countries (LMICs). Major reasons for these shifts include increasing life expectancy and changing diets and lifestyles. An estimated 14·1 million new cases and 8·2 million cancer deaths occurred worldwide in 2012, with more than 65% of cancer deaths occurring in LMICs. [6].

However, the same reproductive factors that protect against one form of cancer increase the risk of the other form. Women who have early and frequent pregnancies and who breastfeed their children have a lower risk of getting breast cancer. Therefore, the risks of using the combined pill in women with current breast cancer or a past history of breast cancer outweigh the benefits. However, there are no contraindications to women with a family history of breast cancer using the combined pill.

Methodology: Descriptive survey that ascertained the association of breast cancer with hormonal contraceptives intake among women aged 15-65 years in Abia State Nigeria was adopted. The study involved data collection and examination of the breast in a procedural format eg inspection and palpation to identify breast lump and any other sign of breast cancer. With the use of questionnaire, the researchers got the women who have used hormonal contraceptives for a long time and the type (s) frequently used. The two method inclined the researchers on the risk associated with breast cancer with the use of hormonal contraceptives.

The selected women were gotten from the six (6) Local Government out of the 17. With the application of simple random sampling both the LGAs and the participants were chosen. The research included girls who have started sexual intercourse and have used hormonal contraceptives and women that have used contraceptive for a long time.

Population of the Study: total number of women was about 1,415,082 population, National Bureau of statistics [7-10]. Projected 2,833,999 women in 2020.Out of this number, 1010 respondents were selected from the 17 LGAs in Abia State who leave in the rural and urban areas.

Sample Size and Technique: The simple random sampling was adopted which gave all the women of the age bracket equal

chance of being selected. Depending on the confidence level and the margin of error [11-14]. The researcher chose a margin error of 2, 5% and a confidence level of 95% since our population is greater than one thousand (1,000,000), you need approximately 400 participants (it is advisable to round to the nearest hundred) for my sample [15-21].

Validity and Reliability of the Instrument: Breast cancers screen experts corrected the questionnaire, which includes doctors, nurses, midwives and analyst ascertained the accuracy of the instrument (questionnaire) The researcher constructed two questionnaires, using different items in each of the questionnaire but designed to measure the same concepts and administer them both to same group of respondents in the same sitting which yielded almost the same showing the reliability of the instructment [22-27].

Instrument for Data Collection and Data Analysis
Questionnaire were divided into A, B and C sections A was demographic data of the respondents [28-39]. Section B was design to collect data on the hormonal contraceptives,section C is the practical viewed the breast examination status[40-46].

All statistical analysis was done using the Statistical Package for Social Scientists (SPSS) version 23. Presented in frequencies and percentages and associations were analyzed using inferential statistics tools such as spearman rank correlation Pearson's product moment correlation (PPMC), creswell correlation coefficient scale and linear regression [47-52]. Results were presented in narrative format, tables and figures [53-60].

Results

Tables 1 and 2: Showed Correlation coefficient Between Breast Cancer and Hormonal Usage
In order to check the incidence of breast cancer, the Spearman's rank correlation is the non-parametric. Given that the test statistic returned a value of 0.079 [61-66].

Since the p-values from the test statistic are greater than 0.05, we fail to reject the null hypothesis and conclude that there is not a sufficient evidence to suggest that hormonal usage influences either breast [67-75].

Ho: There is no statistically significant difference between age of participants using hormonal contraceptives and breast cancer @=0.005

Table 3: showed Age as a Factor to Breast Cancer
In order to ascertain if age can be a significant influencing factor on breast cancer, a Kruskal Wallis H test was conducted. With a p-value 0.094, it can be concluded that there is not enough evidence to conclude that age influences breast cancer.There is no evidence of association between age and breast cancers [76-79].

Since the p-values from the test statistic are greater than 0.05, we fail to reject the null hypothesis and conclude that there is not a sufficient evidence to suggest that age influences either breast [80-83].

Table 4: Shows the Association and Hypothesis Between Intake of Hormonal Contraceptives and Breast Cancer
With the use of Kruskal Wallis H test as well as Mann-Whitney U test were employed. With a p-value of 0.038, there is enough evidence to infer that when one began to use hormonal contraceptives influences incidence of breast cancer [84-95].

Table 1: Showed Result of Correlation Coefficient of Breast Cancer with Hormonal Contraceptives

			What was the Result of The Breast Examination?
Spearman's rho	What was the Result of The Breast Examination?	Correlation Coefficient	1.000
		Sig. (2-tailed)	.
		N	252

Table 2: TEST of Hypothesis
H_o = There is no significant association between breast and hormonal contraceptive usage [96-99].

Decision Rule: Reject if test statistic returns a p-value less than 0.05. Otherwise, accept Ho Mann-Whitney U Test for Influence of Hormonal Contraceptive Usage

Case	Test Statistic value	P-value
Breast Cancer	2156.00	0.506

Table 3: Predictive factor Age (independent variable), and Breast Cancer (Dependent Variables) Using Kruskal Wallis H Test

Ranks	Age Range	N	Mean Rank
What was the Result of The Breast Examination?	(10-20) years	34	122.40
	(21-30) years	40	133.11
	(31-40) years	88	122.73
	(41-50) years	71	123.68
	(51-60) years	14	111.50
	Total	247	

Table 4: Shows the Association and Hypothesis Between Intake of Hormonal Contraceptives and Breast Cancer

Variable	Type of test	Statistic	P-value
Breast cancer and commencement of hormonal contraceptives	Pearson Chi-Square test for Independence	10.168	0.038

Disclosure
No conflicts of interest during the research study.

Declarations
The researchers took consent from the participants and health facilities used

References

1. Kolomeyevskaya, N. V., Szender, J. B., Zirpoli, G., Minlikeeva, A., Friel, G., Cannioto, R. A., ... & Moysich, K. B. (2015). Oral contraceptive use and reproductive characteristics affect survival in patients with epithelial ovarian cancer: a cohort study. International Journal of Gynecologic Cancer, 25(9).

2. Iodice, S., Barile, M., Rotmensz, N., Feroce, I., Bonanni, B., Radice, P., ... & Gandini, S. (2010). Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. European journal of cancer, 46(12), 2275-2284.

3. Gierisch, J. M., Coeytaux, R. R., Urrutia, R. P., Havrilesky, L. J., Moorman, P. G., Lowery, W. J., ... & Myers, E. R. (2013). Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer epidemiology, biomarkers & prevention, 22(11), 1931-1943.

4. Havrilesky, L. J., Moorman, P. G., Lowery, W. J., Gierisch, J. M., Coeytaux, R. R., Urrutia, R. P., ... & Myers, E. R. (2013). Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis. Obstetrics & Gynecology, 122(1), 139-147.

5. Hunter, D. J., Colditz, G. A., Hankinson, S. E., Malspeis, S., Spiegelman, D., Chen, W., ... & Willett, W. C. (2010). Oral contraceptive use and breast cancer: a prospective study of young women. Cancer epidemiology, biomarkers & prevention, 19(10), 2496-2502.

6. Iversen, L., Sivasubramaniam, S., Lee, A. J., Fielding, S., & Hannaford, P. C. (2017). Lifetime cancer risk and combined oral contraceptives: The Royal College of General Practitioners' Oral Contraception Study. American journal of obstetrics and gynecology, 216(6), 580-581.

7. Mahmood, A., & Sultan, M. (2006). National Institute of Population Studies (NIPS)(Pakistan), and Macro International Inc. Pakistan Demographic and Health Survey, 7, 123-145.

8. Burkman, R., Schlesselman, J. J., & Zieman, M. (2004). Safety concerns and health benefits associated with oral contraception. American journal of obstetrics and gynecology, 190(4), S5-S22.

9. Bassuk, S. S., & Manson, J. E. (2015). Oral contraceptives and menopausal hormone therapy: relative and attributable risks of cardiovascular disease, cancer, and other health outcomes. Annals of epidemiology, 25(3), 193-200.

10. Bhupathiraju, S. N., Grodstein, F., Stampfer, M. J., Willett, W. C., Hu, F. B., & Manson, J. E. (2016). Exogenous hormone use: oral contraceptives, postmenopausal hormone therapy, and health outcomes in the Nurses' Health Study. American journal of public health, 106(9), 1631-1637.

11. Beaber, E. F., Buist, D. S., Barlow, W. E., Malone, K. E., Reed, S. D., & Li, C. I. (2014). Recent oral contraceptive use by formulation and breast cancer risk among women 20 to 49 years of age. Cancer research, 74(15), 4078-4089.

12. Karst, A. M., Jones, P. M., Vena, N., Ligon, A. H., Liu, J. F., Hirsch, M. S., …& Drapkin, R. (2014). Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers. Cancer research, 74(4), 1141–1152 doi: 10.1158/0008-5472.CAN-13.

13. Collaborative Group on Epidemiological Studies on Endometrial Cancer. (2015). Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies. The Lancet. Oncology, 16(9), 1061–1070.

14. Iodice, S., Barile, M., Rotmensz, N., Feroce, I., Bonanni, B., Radice, P., …& Gandini, S. (2010). Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. European journal of cancer (Oxford, England: 1990), 46(12), 2275-2284.

15. Mørch, L. S., Skovlund, C. W., Hannaford, P. C., Iversen, L., Fielding, S., & Lidegaard, Ø. (2017). Contemporary hormonal contraception and the risk of breast cancer. New England Journal of Medicine, 377(23), 2228-2239.

16. Collaborative Group on Hormonal Factors in Breast Cancer. (1996). Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. The Lancet, 347(9017), 1713-1727.

17. Evan, G. I., & Vousden, K. H. (2001). Proliferation, cell cycle and apoptosis in cancer. nature, 411(6835), 342-348.

18. Irwin, M. S., & Kaelin, W. G. (2001). p53 family update: p73 and p63 develop their own identities. Cell Growth Different, 12, 337-349.

19. Classon, M., & Harlow, E. (2002). The retinoblastoma tumour suppressor in development and cancer. Nature Reviews Cancer, 2(12), 910-917.

20. Gazdar, A. F., Butel, J. S., & Carbone, M. (2002). SV40 and human tumours: myth, association or causality? Nature Reviews Cancer, 2(12), 957-964.

21. Leblanc, V., & May, P. (2002). Activation et modifications post-traductionnelles de p53 après dommage de l'ADN. médecine/sciences, 18(5), 577-584.

22. Stein, G. S, & Pardee, A. B. (2014). The molecular basis of cell cycle and growth control 2nd ed.

23. Weinberg, R. A. (1996). How cancer arises. Scientific American, 275(3), 62-70.

24. Kinzler, K. W., & Vogelstein, B. (1997). Gatekeepers and caretakers. Nature, 386, 761-762.

25. Ruas, M., & Peters, G. (1998). The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 34, 1-19.

26. Vogelstein, B., Lane, D., & Levine, A. J. (2000). Surfing the p53 network. Nature, 408(6810), 307-310.

27. SHERR. C. J. (2002). "The RB and p53 pathways in cancer." Cancer Cell, 2, 103-112.

28. Zheng, L., & Lee, W. H. (2002). Retinoblastoma tumor suppressor and genome stability. Cancer Res. 85, 13-50.

29. Fridman, J. S., & Lowe, S. W. (2003). Control of apoptosis by p53. Oncogene, 22(56), 9030-9040.

30. Hofseth, L. J., Hussain, S. P., & Harris, C. C. (2004). p53: 25 years after its discovery. Trends in pharmacological sciences, 25(4), 177-181.

31. Iwakuma, T., & Lozano, G. (2013). MDM2, an introduction. Mol Cancer Res, 1, 993-1000.

32. Lowe, S. W., & Sherr, C. J. (2003). Tumor suppression by Ink4a–Arf: progress and puzzles. Current opinion in genetics & development, 13(1), 77-83.

33. Vargas, D. A., Takahashi, S., & Ronai, Z. E. (2003). Mdm2: A regulator of cell growth and death. Advances in cancer research, 89, 1-35.

34. Santarosa, M., & Ashworth, A. (2004). Haploinsufficiency for tumour suppressor genes: when you don't need to go all the way. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 1654(2), 105-122.

35. Sherr, C. J. (2004). Principles of tumor suppression. Cell, 116(2), 235-246.

36. Wentzensen, N., & de Gonzalez, A. B. (2015). The Pill's gestation: from birth control to cancer prevention. The Lancet Oncology, 16(9), 1004-1006. doi: 10.1016/S1470-2045(15)00211-9Exit Disclaimer.

37. Smith, J. S., Green, J., de Gonzalez, A. B., Appleby, P., Peto, J., Plummer, M., ... & Beral, V. (2003). Cervical cancer and use of hormonal contraceptives: a systematic review. The Lancet, 361(9364), 1159-1167.

38. Appleby, P., Beral, V., Berrington de González, A., Colin, D., Franceschi, S., Goodhill, A., ... & Sweetland, S. (2007). International Collaboration of Epidemiological Studies of Cervical, Cancer. Cervical cancer and hormonal contraceptives: Collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet, 370(9599), 1609-1621.

39. Roura, E., Travier, N., Waterboer, T., De Sanjosé, S., Bosch, F. X., Pawlita, M., ... & Castellsagué, X. (2016). The influence of hormonal factors on the risk of developing cervical cancer and pre-cancer: results from the EPIC cohort. PloS one, 11(1), e0147029.

40. Michels, K. A., Pfeiffer, R. M., Brinton, L. A., & Trabert, B. (2018). Modification of the associations between duration of oral contraceptive use and ovarian, endometrial, breast, and colorectal cancers. JAMA oncology, 4(4), 516-521. doi:10.1001/jamaoncol.2017.4942Exit Disclaimer.

41. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. (2012). Pharmaceuticals. Combined estrogen-progestogen contraceptives Exit Disclaimer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, 100, 283-311.

42. Wentzensen, N., Poole, E. M., Trabert, B., White, E., Arslan, A. A., Patel, A. V., ... & Tworoger, S. S. (2016). Ovarian cancer risk factors by histologic subtype: an analysis from the ovarian cancer cohort consortium. Journal of Clinical Oncology, 34(24), 2888-2898.

43. Moorman, P. G., Havrilesky, L. J., Gierisch, J. M., Coeytaux, R. R., Lowery, W. J., Peragallo Urrutia, R., ... & Myers, E. R. (2013). Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. Journal of Clinical Oncology, 31(33), 4188-4198.

44. Friebel, T. M., Domchek, S. M., & Rebbeck, T. R. (2014). Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: a systematic review and meta-analysis. Journal of the National Cancer Institute, 106(6), dju091.

45. Luan, N. N., Wu, L., Gong, T. T., Wang, Y. L., Lin, B., & Wu, Q. J. (2015). Nonlinear reduction in risk for colorectal cancer by oral contraceptive use: a meta-analysis of epidemiological studies. Cancer Causes & Control, 26, 65-78.

46. Murphy, N., Xu, L., Zervoudakis, A., Xue, X., Kabat, G., Rohan, T. E., ... & Gunter, M. J. (2017). Reproductive and menstrual factors and colorectal cancer incidence in the Women's Health Initiative Observational Study. British journal of cancer, 116(1), 117-125.

47. Chandra-Mouli, V., Parameshwar, P. S., Parry, M., Lane, C., Hainsworth, G., Wong, S., ... & Say, L. (2017). A never-before opportunity to strengthen investment and action on adolescent contraception, and what we must do to make full use of it. Reproductive health, 14, 1-13.

48. Darroch, J. E., Woog, V., Bankole, A., & Ashford, L. S. (2016). Adding it up: costs and benefits of meeting the contraceptive needs of adolescents. https://www.guttmacher.org/report/adding-it-meeting-contraceptive-needs-of adolescents.

49. Patton, G. C., Sawyer, S. M., Santelli, J. S., Ross, D. A., Afifi, R., Allen, N. B., ... & Viner, R. M. (2016). Our future: A Lancet commission on adolescent health and wellbeing. The Lancet, 387(10036), 2423-2478. doi:10.1016/S0140-6736(16)00579-1.

50. Population Division, United Nations (UN). (2017). Department of Economic and Social Affairs, World Population Prospects: The 2017 Revision, DVD, New York: UN.

51. Santhya, K. G., & Jejeebhoy, S. J. (2015). Sexual and reproductive health and rights of adolescent girls: Evidence from low-and middle-income countries. Global public health, 10(2), 189-221. doi:10.1080/17441692.2014.986169.

52. Bongaarts, J., Mensch, B. S., & Blanc, A. K. (2017). Trends in the age at reproductive transitions in the developing world: The role of education. Population studies, 71(2), 139-154. doi:10.1080/00324728.2017.1291986.

53. Ross, J., Keesbury, J., & Hardee, K. (2015). Trends in the contraceptive method mix in low-and middle-income countries: analysis using a new "average deviation" measure. Global Health: Science and Practice, 3(1), 34-55.

54. Kalamar, A. M., Tunçalp, Ö., & Hindin, M. J. (2018). Developing strategies to address contraceptive needs of adolescents: exploring patterns of use among sexually active adolescents in 46 low-and middle-income countries. Contraception, 98(1), 36-40.

55. Radovich, E., Dennis, M. L., Wong, K. L., Ali, M., Lynch, C. A., Cleland, J., ... & Benova, L. (2018). Who meets the contraceptive needs of young women in sub-Saharan Africa? Journal of Adolescent Health, 62(3), 273-280.

56. Chandra-Mouli, V., McCarraher, D. R., Phillips, S. J., Williamson, N. E., & Hainsworth, G. (2014). Contraception for adolescents in low- and middle-income countries: needs, barriers, and access. Reproductive health, 11, 1-8.

57. Hindin, M. J., Kalamar, A. M., Thompson, T. A., & Upadhyay, U. D. (2016). Interventions to prevent unintended and repeat pregnancy among young people in low-and middle-income countries: a systematic review of the published and gray literature. Journal of adolescent health, 59(3), S8-S15.

58. Kuruvilla, S., Bustreo, F., Kuo, T., Mishra, C. K., Taylor, K., Fogstad, H., ... & Costello, A. (2016). The Global strategy for women's, children's and adolescents' health (2016–2030): a roadmap based on evidence and country experience. Bulletin of the World Health Organization, 94(5), 398.

59. Reproductive Health Supplies Coalition (RHSC). (2017). Global Contraceptive Commodity Gap Analysis, 2016, https://www.rhsupplies.org/activitiesresources/commodity-gap-analysis/.

60. Miller, N., Weinberger, M., & Skibiak, J. (2018). Global contraceptive commodity gap analysis.

61. Prata, N., Weidert, K., & Sreenivas, A. (2013). Meeting the need: youth and family planning in sub-Saharan Africa. Contraception, 88(1), 83-90.

62. Darroch, J. E. (2018). Adding It Up: The Costs and Benefits of Investing in Family Planning and Maternal and Newborn Health 2017-Estimation Methodology, New York: Guttmacher Institute. https://www.guttmacher.org/report/adding-it-upinvesting-in-contraceptio....

63. Population Division. (2017) UN Department of Economic and Social Affairs, World Contraceptive Use by Marital Status and Age: 2017 Revision, 2017, http://www.un.org/en/development/desa/population/publications/dataset/co....

64. Wheldon, M. C., Dasgupta, A., Ueffing, P., & Kantorová, V. (2017). Age-specific modern contraceptive prevalence among married women in 52 FP2020 focus countries: exploration and modelling. In XXVIII International Population Conference, Cape Town, South Africa. https://iussp.confex.com/iussp/ipc2017/meetingapp.cgi/Paper/6347.

65. Alkema, L., Kantorova, V., Menozzi, C., & Biddlecom, A. (2013). National, regional, and global rates and trends in contraceptive prevalence and unmet need for family planning between 1990 and 2015: a systematic and comprehensive analysis. The Lancet, 381(9878), 1642-1652.

66. Wheldon, M. C., Dasgupta, A., Ueffing, P., & Kantorová, V. (2017). The Role of Hierarchies in a Bayesian Hierarchical Model for Estimating and Projecting Contraceptive Prevalence Among Unmarried Women. In Population Association of America Annual Conference, Chicago, Illinois. https://paa.confex.com/paa/2017/meetingapp.cgi/Paper/15825.

67. Population Division, . (2018). Estimates and Projections of the Number of Women Aged 15–49: Revision, New York: UN Population Division.

68. Hubacher, D., Mavranezouli, I., & McGinn, E. (2008). Unintended pregnancy in sub-Saharan Africa: magnitude of the problem and potential role of contraceptive implants to alleviate it. Contraception, 78(1), 73-78.

69. Benova, L., Cleland, J., Daniele, M. A., & Ali, M. (2017). Expanding method choice in Africa with long-acting methods: IUDs, implants or both? International perspectives on sexual and reproductive health, 43(4), 183-191.

70. Bradle, S. E. K. (2017). Global contraceptive failure rates: Who is most at risk? paper presented at the annual meeting of the Population Association of America, Chicago, IL, USA.

71. Trussell, J. (2011). Contraceptive failure in the United States, Contraception, 83(5), 397-404. doi: 10.1016/j.contraception.2011.01.021.

72. Bearak, J., Popinchalk, A., Alkema, L., & Sedgh, G. (2018). Global, regional, and subregional trends in unintended pregnancy and its outcomes from 1990 to 2014: estimates from a Bayesian hierarchical model. The Lancet Global Health, 6(4), e380-e389.

73. Kantorová, V., New, J. R., Biddlecom, A., & Alkema, L. (2017). Setting ambitious yet achievable targets using probabilistic projections: meeting demand for family planning. Studies in family planning, 48(3), 223-233.

74. Biddlecom, A., Riley, T., Darroch, J. E., Sully, E. A., Kantorová, V., & Wheldon, M. C. (2018). Future scenarios of adolescent contraceptive use, cost and impact in developing regions, New York: Guttmacher Institute.

75. Population Reference Bureau. (2013). World Population Data Sheet," http://www.prb.org/Publications/Datasheets/2012/world-population-data-sheet.aspx.

76. National Institute of Population Studies. (2013). (NIPS) and ICF International, Pakistan Demographic and Health Survey 2012-13, National Institute of Population Studies (NIPS), Islamabad, Pakistan; ICF International, Calverton, Md, USA.

77. Bhutta, Z., Darmstadt, G., Ransom, E. I., Starrs, A. M., & Tinker, A. (2003). Basing newborn and maternal health policies on evidence. Shaping policy for maternal and newborn health: a compendium of case studies. Baltimore: USAID, Bill and Melinda Gates Foundation, JHPIEGO, 5-12.

78. Anthony, D. (2011). The state of the world's children 2011-adolescence: an age of opportunity, 148.

79. Sathar, Z. A., Singh, S., & Fikree, F. F. (2007). Estimating the incidence of abortion in Pakistan. Studies in family planning, 38(1), 11-22.

80. Sirageldin, I., Norris, D., & Hardee, J. G. (1976). Family planning in Pakistan: an analysis of some factors constraining use. Studies in Family Planning, 7(5), 144-154.

81. Pasha, O., Fikree, F. F., & Vermund, S. (2011). Determinants of unmet need for family planning in squatter settlements in Karachi, Pakistan. Asia-Pacific Population Journal, 16(2), 93-108.

82. Kadir, M. M., Fikree, F. F., Khan, A., & Sajan, F. (2003). Do mothers-in-law matter? Family dynamics and fertility decision-making in urban squatter settlements of Karachi, Pakistan. Journal of biosocial science, 35(4), 545-558.

83. Salem, R. M., Bernstein, J., Sullivan, T. M., & Lande, R. (2008). Communication for better health. Population reports, series J, 56.

84. Mahmood, N., & Ringheim, K. (1996). Factors affecting contraceptive use in Pakistan. The Pakistan Development Review, 1-22.

85. Marston, C. (2006). Report of a technical consultation on birth spacing, Geneva, Switzerland.

86. Cleland, J., Bernstein, S., Ezeh, A., Faundes, A., Glasier, A., & Innis, J. (2016). Family planning: the unfinished agenda. The lancet, 368(9549), 1810-1827.

87. Cleland, J., Conde-Agudelo, A., Peterson, H., Ross, J., & Tsui, A. (2012). Contraception and health. The Lancet, 380(9837), 149-156.

88. Stover, J., & Ross, J. (2010). How increased contraceptive use has reduced maternal mortality. Maternal and child health journal, 14, 687-695.

89. Zhu, B. P. (2005). Effect of interpregnancy interval on birth outcomes: findings from three recent US studies. International Journal of Gynecology & Obstetrics, 89, S25-S33.

90. Shaikh, B. T. (2007). "Unmet need for family planning Pakistan: Open Access Journal of Contraception, 1, 113-118.

91. Azmat, S. K., Mustafa, G., Hameed, W., Ali, M., Ahmed, A., & Bilgrami, M. (2012). Barriers and perceptions regarding different contraceptives and family planning practices amongst men and women of reproductive age in rural Pakistan: a qualitative study. Pakistan Journal of Public Health, 2(1), 17-22.

92. Rustagi, N., Taneja, D. K., Kaur, R., & Ingle, G. K. (2010). Factors affecting contraception among women in a minority community in Delhi: a qualitative study. Health Popul Perspect Issues, 33(1), 10-15,

93. Haque, N. (2010). Unmet need for contraceptive: the case of married adolescent women in Bangladesh. Int J Curr Res, 9, 29-35.

94. Tilahun, T., Coene, G., Luchters, S., Kassahun, W., Leye, E., Temmerman, M., & Degomme, O. (2013). Family planning knowledge, attitude and practice among married couples in Jimma Zone, Ethiopia. PloS one, 8(4), e61335.

95. Bernhart, M. H., & Uddin, M. M. (1990). Islam and family planning acceptance in Bangladesh. Studies in Family Planning, 21(5), 287-292.

96. Stover, J., & Ross, J. (2010). How increased contraceptive use has reduced maternal mortality. Maternal and child health journal, 14, 687-695.

97. Zhu, B. P. (2005). Effect of interpregnancy interval on birth outcomes: findings from three recent US studies. International Journal of Gynecology & Obstetrics, 89, S25-S33.

98. Shaikh, B. T. (2010). Unmet need for family planning in Pakistan–PDHS 2006–2007: it's time to re-examine déjà vu. Open Access Journal of Contraception, 113-118.